share_log

Raymond James Maintains Outperform on VBI Vaccines, Lowers Price Target to $6

Benzinga ·  Apr 13, 2023 09:25

Raymond James analyst Steven Seedhouse maintains VBI Vaccines (NASDAQ:VBIV) with a Outperform and lowers the price target from $60 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment